Tempus, a Chicago, IL-based technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, raised an additional $100m in Series G financing at a post-money valuation of $5 billion.
Backers included Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, and funds and accounts managed by T. Rowe Price.
The company is using the additional funds to further enhance its operations and continue its expansion into other disease areas, including diabetes, depression, and cardiology.
Led by Eric Lefkofsky, Founder and CEO, Tempus is focused on advancing precision medicine through its proprietary platform that ingests multi-modal data across major disease types and analyzes that data looking for therapeutically relevant insights. In connecting test results to phenotypic, morphologic, and molecular data, including real-time outcome and response data from electronic health records, Tempus is able to add clinical context to physician-ordered laboratory tests.
At present, the company works with thousands of oncologists across hundreds of medical systems, including over two-thirds of all Academic Medical Centers, touching roughly 30% of all cancer patients in the U.S.
With this latest round, Tempus has raised over $600m since its founding in September 2015.